Outcome of SVT in Children Admitted to AUCH

Outcome of Supraventricular Tachycardia in Children Admitted to Assuit University Children Hospital

The aim of the study is to:

. Assess the outcome of Supraventricular tachycardia , the most effective acute and long-term management strategies and recurrence rates of SVT .

Study Overview

• Status: Not yet recruiting
• Conditions: Supraventricular Tachycardia
• Intervention / Treatment: Other: Not found

Detailed Description

Supraventricular tachycardia (SVT) is the most common symptomatic arrhythmia in the pediatric population, characterized by an abnormally rapid heart rate that originates above the ventricles-typically involving the atrial tissue or the atrioventricular (AV) node. It affects approximately

1 in 500 children. Clinical presentation varies by age. Infants may present with poor feeding, vomiting, irritability, lethargy, diaphoresis, or syncope, and may show signs of congestive heart failure if undiagnosed. Older children may report palpitations, chest discomfort, dizziness, shortness of breath, or syncope . Initial management of pediatric SVT follows the ABCDE approach (Airway, Breathing, Circulation, Disability, Exposure) to assess stability. In stable patients, treatment begins with VAGAL maneuvers, followed by ADENOSINE (0.1 mg/kg IV bolus), if needed. If adenosine fails, antiarrhythmic drugs such as β-blockers, flecainide, or amiodarone may be used. In unstable SVT, immediate synchronized cardioversion (0.5-2 J/kg) is indicated. For recurrent SVT, long-term management may include the FLEA approach: Flecainide, Lifestyle modification, Electrophysiologic study, and Ablation. Paroxysmal supraventricular tachycardias (SVTs) are considered benign if the electrocardiogram in sinus rhythm is normal, but their occurrence in children/teenagers is often associated with anxiety in parents, children and their doctors, and sometimes with embarrassing and invalidating symptoms.Invasive evaluation of tachycardia is rarely indicated for several reasons, including misdiagnosis or fear of hospitalization. Frequently, children/teenagers who complain of palpitations or tachycardia are only considered to be anxious, and for several months or years a false diagnosis of sinus tachycardia is given. It is important to provide education and counseling to patients and their families, including information about the condition, treatment options, potential complications, and psychological support. Outcomes of Supraventricular Tachycardia (SVT) in Children, Most children recover fully, either by outgrowing SVT or with curative ablation. Long-term survival is excellent, with no reduction in life expectancy in isolated SVT.. About 30-50% of infants outgrow SVT by age 1-2 . 70-85% of children do well with medications . <5% of infants with untreated SVT may develop heart failure . <1% are at risk of serious events like sudden death . Over 95% grow and develop normally. In this study, the outcome of SVT in pediatrics is assessed including the clinical and electrophysiological data , the most effective acute and long-term management and recurrence rates.

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Sameh Mounir Moussa Soliman; Phone Number: 01001960035; Email: Samehmounir24@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

All with the required criteria

Description

Inclusion Criteria:

• Children aged greater than 1 month and up to 18 years
• Diagnosis of supraventricular tachycardia (SVT) based on:
• Clinical presentation
• Electrocardiogram (ECG) findings

Exclusion Criteria:

• Presence of structural heart disease
• Incomplete clinical data
• Lost to follow-up during the study period

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Outcome of Supraventricular tachycardia in children and recurrence rates	Assess the outcome of Supraventricular tachycardia , the most effective acute and long-term management strategies and recurrence rates of SVT .	Baseline

Collaborators and Investigators

• Sponsor: Assiut University

Publications and helpful links

General Publications

• Hafeez Y, Quintanilla Rodriguez BS, Ahmed I, Grossman SA. Paroxysmal Supraventricular Tachycardia. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507699/
• Nasir M, Sturts A, Sturts A. Common Types of Supraventricular Tachycardia: Diagnosis and Management. Am Fam Physician. 2023 Jun;107(6):631-641.

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): August 1, 2026

Study Registration Dates

• First Submitted: August 20, 2025
• First Submitted That Met QC Criteria: August 20, 2025
• First Posted (Estimated): August 27, 2025

Study Record Updates

• Last Update Posted (Actual): September 2, 2025
• Last Update Submitted That Met QC Criteria: August 26, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiac Conduction System Disease; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Tachycardia; Pathological Conditions, Signs and Symptoms; Tachycardia, Supraventricular
• Other Study ID Numbers: Outcome of SVT in children

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No